|drug1198||Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki||0.71|
|D003428||Cross Infection NIH||0.58|
|D003141||Communicable Diseases NIH||0.08|
There is one clinical trial.
Thousands of healthcare workers have been infected with SARS-CoV-2 and contracted COVID-19 despite their best efforts to prevent contamination. No proven vaccine is available to protect healthcare workers against SARS-CoV-2. This study will enroll 470 healthcare professionals dedicated to care for patients with proven SARS-CoV-2 infection. Subjects will be randomized either in the observational (control) group or in the inhaled nitric oxide group. All personnel will observe measures on strict precaution in accordance with WHO and the CDC regulations.
Description: Percentage of subjects with COVID-19 diagnosis in the two groupsMeasure: COVID-19 diagnosis Time: 14 days
Description: Percentage of subjects with a positive test in the two groupsMeasure: Positive SARS-CoV-2 rt-PCR test Time: 14 days
Description: Mean/ Median in the two groupsMeasure: Total number of quarantine days Time: 14 days
Description: Percentage in the two groupsMeasure: Proportion of healthcare providers requiring quarantine Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports